Carl Voegtlin
Swiss-American pharmacologist (1879-1960) / From Wikipedia, the free encyclopedia
Carl Voegtlin (July 28, 1879 – April 9, 1960), also Karl Voegtlin, was a Swiss-American pharmacologist, organic chemist, and the first director of the U.S. National Cancer Institute.[2] He is known for his research into the biochemical effects of cancer,[3] contributions to the pharmacology of arsenicals[4][5] and the discovery, with Homer Smith, of mapharsen as the active agent in Paul Ehrlich's Salvarsan.[1][6][7][8][9]
Quick Facts Born, Died ...
Carl Voegtlin | |
---|---|
Born | (1879-07-28)July 28, 1879 |
Died | April 9, 1960(1960-04-09) (aged 80) |
Occupation(s) | pharmacologist, organic chemist |
Academic background | |
Education | University of Basel University of Munich University of Freiburg |
Doctoral advisor | Ludwig Gattermann |
Academic work | |
Institutions | University of Wisconsin–Madison Johns Hopkins University United States Public Health Service National Cancer Institute |
Close